DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Poly-Pred (Prednisolone Acetate / Neomycin Sulfate / Polymyxin B Sulfate Ophthalmic) - Summary

 
 



POLY-PRED SUMMARY

POLY-PRED®
(prednisolone acetate, neomycin sulfate, polymyxin B
sulfate ophthalmic suspension, USP)

POLY-PRED® (prednisolone acetate, neomycin sulfate, polymyxin B sulfate ophthalmic suspension, USP) is a topical anti-inflammatory/anti-infective combination product for ophthalmic use with a pH of 5.0 - 7.0 and an osmolality of 260-340 mOsm/kg.

A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus; Escherichia coli; Hemophilus influenzae; Klebsiella/ Enterobacter species; Neisseria species; and Pseudomonas aeruginosa.

The product does not provide adequate coverage against: Serratia marcescens; Streptococci, including Streptococcus pneumoniae.


See all Poly-Pred indications & dosage >>

NEWS HIGHLIGHTS


Page last updated: 2006-05-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017